The University of Texas

University Park, MD, United States

The University of Texas

University Park, MD, United States

Time filter

Source Type

-- Westmount Realty Capital, LLC (http://www.westmountrc.com/)("Westmount"), a Dallas-based commercial real estate development and investment management company, is pleased to announce that Kevin Michels has joined the company as Director – Investment Analysis. In this role, Michels will provide analysis of Westmount's multifamily portfolio and assist with our strategic evaluation of future opportunities, both commercial and multifamily."Westmount's investment strategy requires a strict analysis of defined criteria for each property type and Kevin will be integral to this process," said Clifford Booth, president and CEO of Westmount. "We're confident that Kevin's extensive experience of analyzing asset performance and market conditions will provide valuable insight that will strengthen our investment decisions."Michels has 14 years of experience in commercial real estate with a primary focus on asset analysis and evaluation. Prior to joining Westmount, he was vice president – realty services at Irving, Texas-based C-III Capital Partners LLC, where he facilitated the disposition of 54 assets totaling approximately 7 million square feet of commercial real estate across various asset classes with a combined market value of more than $450 million. While at C-III Capital Partners, Michels was also vice president – investment management where he was responsible for managing a portfolio of approximately 52 properties in excess of $1 billion in total asset value.Prior to joining C-III Capital Partners, Michels was a senior associate in acquisitions and capital markets at Cambridge Healthcare Properties Inc. where he managed a portfolio of 14 properties. He also worked as an underwriter in the due diligence division of Bear Stearns Companies Inc. where he analyzed multi-million dollar loan portfolios to verify the loans met investment parameters to decrease risk exposure.Michels holds a real estate brokers license from the Texas Real Estate Commission ( https://www.trec.texas.gov/ ). He has a bachelor's degree in business economics from The University of Texas ( http://www.utexas.edu/ ) and a master's degree in land and real estate development and finance from Texas A&M University (https://www.tamu.edu/). Michels is an active member of Texas Exes and was a chairman for the Texas A&M Real Estate Association.Westmount Realty Capital, LLC is a time-tested, privately held, Dallas-based commercial real estate company that has achieved exceptional performance, with a core team in place, for more than 30 years. Westmount is seen as an innovator and leading edge company in the industry and is a trusted operating partner of numerous U.S. and foreign institutional and private capital sources. The company is active nationally, specializing in value add and opportunistic investments, and has navigated successfully through multiple market cycles. For additional information, contact www.westmountrc.com.


HOUSTON, May 10, 2017 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ:PLXP) (“PLx” or the “Company”), a specialty pharmaceutical company, has been awarded a $1.9 million grant by the National Cancer Institute (NCI) of the National Institutes of Health (NIH) in support of PLx’s novel formulation of aspirin for chemoprevention of colorectal cancer. “This NCI grant will enable us to further advance research of our novel formulation of aspirin for the prevention of colorectal cancer, the fourth most commonly diagnosed cancer in the U.S. today,” stated Natasha Giordano, President and Chief Executive Officer of PLx. The role of aspirin in platelet pharmacology is well-established, and aspirin itself remains the foundational drug used for cardiovascular disease prevention. Dr. Lenard M. Lichtenberger, Professor of Integrative Biology & Pharmacology at The University of Texas Health Science Center at Houston (UTHealth), will be the Principal Investigator of studies funded by this grant. The research will be conducted at UTHealth, Baylor College of Medicine and The University of Texas MD Anderson Cancer Center and will focus on further investigating this novel formulation of aspirin’s role in colorectal cancer prevention. Further development of PLx’s novel phosphatidylcholine (PC)-associated aspirin (Aspirin-PC) for the prevention of colorectal cancer and potentially other cancers is supported by two recently published studies in peer-reviewed journals of the American Association for Cancer Research (AACR). Cancer Prevention Research (February 2017) published a study by Dr. Lichtenberger et al on the mechanism of Aspirin-PC in colon cancer, both in cell culture and in a chemically-induced murine model of colon cancer.1   This study demonstrated Aspirin-PC’s activity with regard to antiplatelet effect and chemoprevention in these preclinical models. A December 2016 paper published in Molecular Cancer Therapeutics described in vitro dose response studies comparing the growth-inhibitory effect of Aspirin-PC versus regular aspirin on three human and one murine ovarian cancer cell line over an 8-day culture period and three independent mouse models of ovarian cancer, two carrying different cell lines of human ovarian cancer and one where a mouse ovarian cancer cell line was passaged.2 These studies, conducted by Dr. Anil Sood and co-first authors Dr. Yan Huang and Dr. Lichtenberger, et al, demonstrated Aspirin-PC’s activity in inhibiting ovarian cancer growth under both in vitro and in vivo conditions.  Drs. Sood and Huang were with MD Anderson Cancer Center, while Dr. Lichtenberger led a team at UTHealth that included Drs. Elizabeth Dial and Dexing Fang. The NCI grant, Award Number R42CA171408, will be disbursed in two installments: $961,499 in 2017 and $966,160 in 2018. 2 Huang Y et al. Antitumor and Antiangiogenic Effects of Aspirin-PC in Ovarian Cancer. Mol Cancer Ther; 15(12) December 2016. PLx Pharma Inc. is a specialty pharmaceutical company focused on developing its clinically validated and patent-protected PLxGuard™ delivery system to provide safe and effective aspirin products. PLx Pharma’s lead product Aspertec™ Aspirin Capsules, 325 mg is FDA approved.  PLx is focused on completing manufacturing scale-up and label finalization for Aspertec 325 mg aspirin dose strength and preparing an sNDA for Aspertec 81 mg maintenance dose strength. PLxGuard works by targeting delivery of active pharmaceutical ingredients to various portions of the gastrointestinal (GI) tract. PLx believes this delivery system has the potential to improve the absorption of many drugs currently on the market or in development, such as aspirin, and may provide high-risk cardiovascular and stroke patients with more reliable and predictable antiplatelet efficacy as compared to enteric coated aspirin. PLx also believes PLxGuard has the potential to reduce acute GI side effects—including erosions, ulcers and bleeding—associated with aspirin and ibuprofen, and potentially other drugs. To learn more about PLx Pharma Inc. and its pipeline, please visit www.plxpharma.com. NCI leads the National Cancer Program and the NIH’s efforts to dramatically reduce the prevalence of cancer and improve the lives of cancer patients and their families, through research into prevention and cancer biology, the development of new interventions, and the training and mentoring of new researchers. For more information about cancer, please visit the NCI website at cancer.gov or call NCI's Cancer Information Service at 1-800-4-CANCER. About the National Institutes of Health (NIH) NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit nih.gov. Any statements made in this press release relating to future financial or business performance, conditions, plans, prospects, trends, or strategies and other financial and business matters, including without limitation, the prospects for commercializing or selling any products or drug candidates, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In addition, when or if used in this press release, the words “may,” “could,” “should,” “anticipate,” “believe,” “estimate,” “expect,” “intend,” “plan,” “predict” and similar expressions and their variants, as they relate to PLx may identify forward-looking statements. PLx cautions that these forward-looking statements are subject to numerous assumptions, risks, and uncertainties, which change over time. Important factors that may cause actual results to differ materially from the results discussed in the forward-looking statements or historical experience include risks and uncertainties, including the failure by PLx to secure and maintain relationships with collaborators; risks relating to clinical trials; risks relating to the commercialization, if any, of PLx’s proposed product candidates (such as marketing, regulatory, product liability, supply, competition, and other risks); dependence on the efforts of third parties; dependence on intellectual property and risks that PLx may lack the financial resources and access to capital to fund proposed operations. Further information on the factors and risks that could affect PLx’s business, financial conditions and results of operations are contained in PLx’s filings with the U.S. Securities and Exchange Commission (SEC), which are available at www.sec.gov. Other risks and uncertainties are more fully described in the Registration Statement on Form S-4 filed with the SEC in connection with the merger of PLx and Dipexium Pharmaceuticals, Inc., and in other filings that PLx will make going forward. The forward-looking statements represent PLx’s estimate as of the date hereof only, and PLx specifically disclaims any duty or obligation to update forward-looking statements.


News Article | May 11, 2017
Site: www.biosciencetechnology.com

UT Health San Antonio researchers discovered epigenetic changes that contribute to one-fifth of cases of acute myeloid leukemia (AML), an aggressive cancer that arises out of the blood-forming cells in bone marrow. The mutations also play a role in a large majority of low-grade gliomas, which are among the most-treatable brain tumors. The UT Health scientists describe the finding in this week's issue of Cancer Cell. "The best way to treat a cancer is to understand it," said Ricardo C.T. Aguiar, M.D., Ph.D., professor of medicine at The University of Texas Health Science Center, now called UT Health San Antonio. "We have added to the understanding of a broad swath of cancers that carry what is called the IDH mutation." Dr. Aguiar, a hematology-oncology researcher and member of the UT Health San Antonio Cancer Center, is senior author of the study. He said in the future cancers will be classified not by where they are located but by their genetic defect - such as the IDH mutation. IDH is short for isocitrate dehydrogenase. The UT Health team found that IDH mutations alter an epigenetic process called RNA methylation, which leads to deregulation of hundreds of other genes and processes inside the tumor cell. Changes that amplify -- or silence -- genes Epigenetic modifications change gene activity but don't structurally change the body's genetic blueprints. Diet, aging, environmental exposure and other factors can prompt epigenetic changes that amplify or silence certain genes. A drug that inhibits the IDH mutant enzymes is in non-UT Health-related clinical trials. The UT Health discovery provides evidence for why the drug may help patients with AML and low-grade gliomas. "Acute myeloid leukemia remains a very difficult-to-treat tumor and, unfortunately, the majority of patients still die of their disease," Dr. Aguiar said. "In this paper, in addition to sophisticated genetic models created in our lab, we also studied primary AML samples to demonstrate that, in the very IDH-mutant tumors from the patients, we detected this change in RNA methylation. By better understanding how the IDH-dependent cancers work, we may be able to fine-tune future therapies and improve survival."


News Article | May 10, 2017
Site: www.eurekalert.org

SAN ANTONIO, Texas, U.S.A -- UT Health San Antonio researchers discovered epigenetic changes that contribute to one-fifth of cases of acute myeloid leukemia (AML), an aggressive cancer that arises out of the blood-forming cells in bone marrow. The mutations also play a role in a large majority of low-grade gliomas, which are among the most-treatable brain tumors. The UT Health scientists describe the finding in this week's issue of Cancer Cell. "The best way to treat a cancer is to understand it," said Ricardo C.T. Aguiar, M.D., Ph.D., professor of medicine at The University of Texas Health Science Center, now called UT Health San Antonio. "We have added to the understanding of a broad swath of cancers that carry what is called the IDH mutation." Dr. Aguiar, a hematology-oncology researcher and member of the UT Health San Antonio Cancer Center, is senior author of the study. He said in the future cancers will be classified not by where they are located but by their genetic defect - such as the IDH mutation. IDH is short for isocitrate dehydrogenase. The UT Health team found that IDH mutations alter an epigenetic process called RNA methylation, which leads to deregulation of hundreds of other genes and processes inside the tumor cell. Changes that amplify -- or silence -- genes Epigenetic modifications change gene activity but don't structurally change the body's genetic blueprints. Diet, aging, environmental exposure and other factors can prompt epigenetic changes that amplify or silence certain genes. A drug that inhibits the IDH mutant enzymes is in non-UT Health-related clinical trials. The UT Health discovery provides evidence for why the drug may help patients with AML and low-grade gliomas. "Acute myeloid leukemia remains a very difficult-to-treat tumor and, unfortunately, the majority of patients still die of their disease," Dr. Aguiar said. "In this paper, in addition to sophisticated genetic models created in our lab, we also studied primary AML samples to demonstrate that, in the very IDH-mutant tumors from the patients, we detected this change in RNA methylation. By better understanding how the IDH-dependent cancers work, we may be able to fine-tune future therapies and improve survival." The work in Dr. Aguiar's lab was co-led by postdoctoral fellow Sara Elkashef, Ph.D., and Research Scientist An-Ping Lin, M.D. Patricia Dahia, M.D., Ph.D., professor of medicine at UT Health San Antonio, and Heinz Sill, M.D., University of Graz, Austria, collaborated with Dr. Aguiar's group in this project. This research was funded by an award from the Cancer Prevention & Research Institute of Texas. Dr. Aguiar is also funded by the Leukemia and Lymphoma Society. Learn more about acute myeloid leukemia from the UT Health San Antonio Cancer Center. For current news from the UT Health Science Center San Antonio, now called UT Health San Antonio™, please visit our online newsroom, like us on Facebook or follow us on Twitter. The University of Texas Health Science Center at San Antonio, with missions of teaching, research and healing, is one of the country's leading health sciences universities and is now called UT Health San Antonio™. UT Health's schools of medicine, nursing, dentistry, health professions and graduate biomedical sciences have produced more than 33,000 alumni who are advancing their fields throughout the world. With four campuses in San Antonio and Laredo, UT Health has a FY 2017 revenue operating budget of $806.6 million and is the primary driver of its community's $37 billion biomedical and health care industry. For more information on the many ways "We make lives better®," visit http://www. .


HOUSTON, May 10, 2017 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ:PLXP) (“PLx” or the “Company”), a specialty pharmaceutical company, has been awarded a $1.9 million grant by the National Cancer Institute (NCI) of the National Institutes of Health (NIH) in support of PLx’s novel formulation of aspirin for chemoprevention of colorectal cancer. “This NCI grant will enable us to further advance research of our novel formulation of aspirin for the prevention of colorectal cancer, the fourth most commonly diagnosed cancer in the U.S. today,” stated Natasha Giordano, President and Chief Executive Officer of PLx. The role of aspirin in platelet pharmacology is well-established, and aspirin itself remains the foundational drug used for cardiovascular disease prevention. Dr. Lenard M. Lichtenberger, Professor of Integrative Biology & Pharmacology at The University of Texas Health Science Center at Houston (UTHealth), will be the Principal Investigator of studies funded by this grant. The research will be conducted at UTHealth, Baylor College of Medicine and The University of Texas MD Anderson Cancer Center and will focus on further investigating this novel formulation of aspirin’s role in colorectal cancer prevention. Further development of PLx’s novel phosphatidylcholine (PC)-associated aspirin (Aspirin-PC) for the prevention of colorectal cancer and potentially other cancers is supported by two recently published studies in peer-reviewed journals of the American Association for Cancer Research (AACR). Cancer Prevention Research (February 2017) published a study by Dr. Lichtenberger et al on the mechanism of Aspirin-PC in colon cancer, both in cell culture and in a chemically-induced murine model of colon cancer.1   This study demonstrated Aspirin-PC’s activity with regard to antiplatelet effect and chemoprevention in these preclinical models. A December 2016 paper published in Molecular Cancer Therapeutics described in vitro dose response studies comparing the growth-inhibitory effect of Aspirin-PC versus regular aspirin on three human and one murine ovarian cancer cell line over an 8-day culture period and three independent mouse models of ovarian cancer, two carrying different cell lines of human ovarian cancer and one where a mouse ovarian cancer cell line was passaged.2 These studies, conducted by Dr. Anil Sood and co-first authors Dr. Yan Huang and Dr. Lichtenberger, et al, demonstrated Aspirin-PC’s activity in inhibiting ovarian cancer growth under both in vitro and in vivo conditions.  Drs. Sood and Huang were with MD Anderson Cancer Center, while Dr. Lichtenberger led a team at UTHealth that included Drs. Elizabeth Dial and Dexing Fang. The NCI grant, Award Number R42CA171408, will be disbursed in two installments: $961,499 in 2017 and $966,160 in 2018. 2 Huang Y et al. Antitumor and Antiangiogenic Effects of Aspirin-PC in Ovarian Cancer. Mol Cancer Ther; 15(12) December 2016. PLx Pharma Inc. is a specialty pharmaceutical company focused on developing its clinically validated and patent-protected PLxGuard™ delivery system to provide safe and effective aspirin products. PLx Pharma’s lead product Aspertec™ Aspirin Capsules, 325 mg is FDA approved.  PLx is focused on completing manufacturing scale-up and label finalization for Aspertec 325 mg aspirin dose strength and preparing an sNDA for Aspertec 81 mg maintenance dose strength. PLxGuard works by targeting delivery of active pharmaceutical ingredients to various portions of the gastrointestinal (GI) tract. PLx believes this delivery system has the potential to improve the absorption of many drugs currently on the market or in development, such as aspirin, and may provide high-risk cardiovascular and stroke patients with more reliable and predictable antiplatelet efficacy as compared to enteric coated aspirin. PLx also believes PLxGuard has the potential to reduce acute GI side effects—including erosions, ulcers and bleeding—associated with aspirin and ibuprofen, and potentially other drugs. To learn more about PLx Pharma Inc. and its pipeline, please visit www.plxpharma.com. NCI leads the National Cancer Program and the NIH’s efforts to dramatically reduce the prevalence of cancer and improve the lives of cancer patients and their families, through research into prevention and cancer biology, the development of new interventions, and the training and mentoring of new researchers. For more information about cancer, please visit the NCI website at cancer.gov or call NCI's Cancer Information Service at 1-800-4-CANCER. About the National Institutes of Health (NIH) NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit nih.gov. Any statements made in this press release relating to future financial or business performance, conditions, plans, prospects, trends, or strategies and other financial and business matters, including without limitation, the prospects for commercializing or selling any products or drug candidates, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In addition, when or if used in this press release, the words “may,” “could,” “should,” “anticipate,” “believe,” “estimate,” “expect,” “intend,” “plan,” “predict” and similar expressions and their variants, as they relate to PLx may identify forward-looking statements. PLx cautions that these forward-looking statements are subject to numerous assumptions, risks, and uncertainties, which change over time. Important factors that may cause actual results to differ materially from the results discussed in the forward-looking statements or historical experience include risks and uncertainties, including the failure by PLx to secure and maintain relationships with collaborators; risks relating to clinical trials; risks relating to the commercialization, if any, of PLx’s proposed product candidates (such as marketing, regulatory, product liability, supply, competition, and other risks); dependence on the efforts of third parties; dependence on intellectual property and risks that PLx may lack the financial resources and access to capital to fund proposed operations. Further information on the factors and risks that could affect PLx’s business, financial conditions and results of operations are contained in PLx’s filings with the U.S. Securities and Exchange Commission (SEC), which are available at www.sec.gov. Other risks and uncertainties are more fully described in the Registration Statement on Form S-4 filed with the SEC in connection with the merger of PLx and Dipexium Pharmaceuticals, Inc., and in other filings that PLx will make going forward. The forward-looking statements represent PLx’s estimate as of the date hereof only, and PLx specifically disclaims any duty or obligation to update forward-looking statements.


Receive press releases from Pulmotect, Inc: By Email US China Innovation and Investment Summit Panel on Biopharmaceuticals to Feature Pulmotect CEO Molfino, a respiratory medicine specialist, will provide his perspective on balancing the costs of developing and delivering innovative technologies, drug safety and regulatory issues, important learnings to date and the future outlook of therapeutics in modern healthcare. Houston, TX, May 10, 2017 --( The 40-minute panel discussion will take place at 1 p.m. in Colonnade Salon A. Industry experts joining Molfino in the discussion on therapeutics are Mike Moradi, CEO and co-founder of Sensulin and Jon Northrup, CEO and co-founder of Beta Cat Pharmaceuticals. Molfino, a respiratory medicine specialist, will provide his perspective on balancing the costs of developing and delivering innovative technologies, drug safety and regulatory issues, important learning to date and the future outlook of therapeutics in modern healthcare. Molfino previously served as an independent consultant to biopharmaceutical companies, clinical research organizations (CROs), investors and patient organizations in the planning, designing and execution of drug development and commercial strategies. He was also the Chief Medical Officer at South San Francisco-based KaloBios Pharmaceuticals, Inc. In addition to the panel discussion, Molfino will represent Pulmotect in the InnoSTARS preliminary stage pitch competition on Monday, May 15 for a chance to earn an expense-paid trip to China to showcase the company’s technology to potential partners and investors during a three-city tour. The US China Innovation and Investment Summit will focus on five areas of industry including healthcare and biotechnology, agriculture and food safety, renewable energy, advanced manufacturing and information and communication technology. In addition to panel discussions, the summit will feature B2B Matchmaking sessions, an exhibition of technology companies and VIP meetings. To learn more about the 2017 conference, visit http://uschinainnovation.org. About Pulmotect, Inc. Founded in 2007, Pulmotect’s technology is licensed from The Texas A&M University System and The University of Texas MD Anderson Cancer Center. Pulmotect partnered in 2008 with Fannin Innovation Studio, a Houston-based early-stage life science management and investment company, to assist in the drug’s commercial development. Pulmotect is the recipient of multiple early stage investments and grants, as well as recognition and awards from the biotechnology community, and the Company was awarded $7.1 million from the Cancer Prevention Institute of Texas (CPRIT). For more information, visit www.pulmotect.com. Houston, TX, May 10, 2017 --( PR.com )-- Pulmotect, Inc., clinical stage biotechnology company developing and commercializing an inhalant designed to prevent respiratory infections, announced today that Nestor Molfino, M.D., CEO, will participate in a panel discussion entitled “Innovation in Biopharmaceuticals” at the US China Innovation and Investment Summit, being held at the Omni Houston Hotel in Houston, Texas on May 16, 2017.The 40-minute panel discussion will take place at 1 p.m. in Colonnade Salon A. Industry experts joining Molfino in the discussion on therapeutics are Mike Moradi, CEO and co-founder of Sensulin and Jon Northrup, CEO and co-founder of Beta Cat Pharmaceuticals.Molfino, a respiratory medicine specialist, will provide his perspective on balancing the costs of developing and delivering innovative technologies, drug safety and regulatory issues, important learning to date and the future outlook of therapeutics in modern healthcare.Molfino previously served as an independent consultant to biopharmaceutical companies, clinical research organizations (CROs), investors and patient organizations in the planning, designing and execution of drug development and commercial strategies. He was also the Chief Medical Officer at South San Francisco-based KaloBios Pharmaceuticals, Inc.In addition to the panel discussion, Molfino will represent Pulmotect in the InnoSTARS preliminary stage pitch competition on Monday, May 15 for a chance to earn an expense-paid trip to China to showcase the company’s technology to potential partners and investors during a three-city tour.The US China Innovation and Investment Summit will focus on five areas of industry including healthcare and biotechnology, agriculture and food safety, renewable energy, advanced manufacturing and information and communication technology. In addition to panel discussions, the summit will feature B2B Matchmaking sessions, an exhibition of technology companies and VIP meetings.To learn more about the 2017 conference, visit http://uschinainnovation.org.About Pulmotect, Inc.Founded in 2007, Pulmotect’s technology is licensed from The Texas A&M University System and The University of Texas MD Anderson Cancer Center. Pulmotect partnered in 2008 with Fannin Innovation Studio, a Houston-based early-stage life science management and investment company, to assist in the drug’s commercial development. Pulmotect is the recipient of multiple early stage investments and grants, as well as recognition and awards from the biotechnology community, and the Company was awarded $7.1 million from the Cancer Prevention Institute of Texas (CPRIT). For more information, visit www.pulmotect.com. Click here to view the list of recent Press Releases from Pulmotect, Inc


Patent
The University Of Texas and Mission Pharmacal Co. | Date: 2011-06-07

Small molecules and their derivatives are described for the treatment and/or prevention of intestinal fluid loss. Also disclosed are methods of using said molecules and their derivatives to treat and/or prevent conditions associated with increased levels of 3,5-adenosine monophosphate. Specific compositions of the invention are also novel.


Grant
Agency: Department of Defense | Branch: Air Force | Program: STTR | Phase: Phase II | Award Amount: 705.40K | Year: 2013

ABSTRACT: The leading errors in computing future positions of satellites in Low Earth Orbit are generally due to inaccuracies in the thermospheric density and the prediction thereof. The use of Dynamic Calibration Atmosphere has reduced these traditional sources of error and variations seen in ballistic coefficients can now be attributed to unmodeled satellite frontal area changes. When the orbit of a satellite needs to be predicted, a value is assumed. The assumed value of the ballistic coefficient will cause the predicted orbit to be in error. Hence, considerable improvement in the quality of orbit prediction can be achieved by reducing that error. The ballistic coefficient for prediction is usually obtained from the estimated value prior to the prediction. Instead of assuming the previous estimated value, an analysis of the time series of a history of the estimated values may reveal some characteristics which then can be used to minimize prediction error. BENEFIT: The Phase II effort will result in a software toolset that will improve ballistic coefficient modeling resulting in enhanced orbit prediction. This is of particular benefit to the conjunction assessment mission, improving warning and risk mitigation timelines and accuracy. The toolset will be made available to satellite owner/operators, commercial foreign entities and the defense community. Additionally, the toolset may be provided as a plug-in for commercial software applications such as STK and FreeFlyer.


Disclosed are surprising discoveries concerning the role of anionic phospholipids and aminophospholipids in tumor vasculature and in viral entry and spread, and compositions and methods for utilizing these findings in the treatment of cancer and viral infections. Also disclosed are advantageous antibody, immunoconjugate and duramycin-based compositions and combinations that bind and inhibit anionic phospholipids and aminophospholipids, for use in the safe and effective treatment of cancer, viral infections and related diseases.


The invention provides a conjugate comprising ethylenedicysteine (EC) conjugated to neomycin.

Loading The University of Texas collaborators
Loading The University of Texas collaborators